

# A Study on Toxicity and Tolerability of Tenofovir in Tenofovir based First Line Anti Retroviral Therapy in ART Naïve Patients

Dr MD Mohiuddin Sk<sup>1</sup>, Dr Kapildev Mondal<sup>2\*</sup>, Dr Subarna Kundu<sup>3</sup>

<sup>1</sup>R.M.O Cum Clinical Tutor, Department of General Medicine, Murshidabad Medical College & Hospital, West Bengal, India

<sup>2</sup>Assistant Professor, Department of General Medicine, Murshidabad Medical College & Hospital, West Bengal, India

<sup>3</sup>Junior Resident, Department of Pathology, North Bengal Medical College & Hospital, West Bengal, India

\*Corresponding Author: Dr Kapildev Mondal

## 1. Introduction & Background

Tenofovir has been recently introduced in our country as first line therapy in HIV infection but limited data available on safety profile (special concern is its association with nephrotoxicity) tolerability in Indian population of patients.

The main concern is Nephrotoxicity of Tenofovir and the study will focus on toxicity, particularly nephrotoxicity & tolerability of Tenofovir in Tenofovir based 1st line ART regimens as none of the other drugs in these regimens are Nephrotoxic.

## 2. Methods

We took approval from Institutional ethics committee & Informed consent from all the study subjects. We studied subjects from July to December 2014 and followed up of each for 6 months, collected detailed history did physical examinations and baseline investigations before initiation of ART and subsequently at 2weeks, 1 month, 3 month and 6 month of starting of ART. We assessed tolerability to the regimens by symptoms of patients (nausea, vomiting, loss of appetite etc) and laboratory tests report. We collected all data data & analyzed by using SPSS.

## 3. Discussion

HIV infection causes significant morbidity and mortality by causing an immune deficient state and patients usually succumb to death from unusual opportunistic infections and malignancies. However HIV infection is a manageable with HAART. We conducted the study involving 97 eligible patients who were followed up for a period of 6 months. We studied toxicity and tolerability of tenofovir.

We observed gastrointestinal intolerance which includes anorexia, nausea, vomiting and upper abdominal pain in 12.37% patients at 2 weeks of starting of ART which subsequently relieved with time. Only 4% patients had GI intolerance at 1 month which relieved after few days. We found that there is increment in mean haemoglobin level of total study population from base line value. There was no effect on mean total and differential leucocyte count and also on the mean platelet count.

We found no adverse effect of the drug on liver function (serum bilirubin, SGOT, SGPT did not show any change).

The study showed that there is increasing value of mean serum creatinine level of total study population from base line value but mean serum creatinine at the end of study remained within normal reference value. None of the study population developed acute renal failure or feature of proximal renal tubular dysfunction (glycosuria in presence of normal plasma glucose and proteinuria) for which discontinuation of tenofovir required. The pattern of change in serum creatinine level is same in both sex group.

We also found that there was increasing value of mean serum urea level of the total study population from base line value although the value at the end of study remained within normal reference value.

We found there is clinical, biochemical and improvement of overall health in general of the study population probably due to well control of the disease and also the control of opportunistic infection. The study population had overall weight gain at the end of the study

## 4. Results

This study shows that tenofovir is well tolerated drug in this population of patients with once daily regimen which has improved patients compliance. Tenofovir therapy improves overall general health of the patients. Tenofovir therapy is associated with mean weight gain and increased in haemoglobin level. It is not associated with adverse effect on total leucocyte count, differential leucocyte count, platelet count, serum bilirubin and serum liver enzymes (SGOT, SGPT). Within this 6 month follow up, evidence of nephropathy or proximal renal tubulopathy is not seen in any study subject.

## 5. Conclusion

Tenofovir is well tolerate and very safe drug in these patients without prior renal disease and concurrent nephrotoxic drugs, the follow up of these patients should be done to know the exact incidence of nephropathy as literature has concerned us about the possibility of renal toxicity with tenofovir with prolonged exposure.

Volume 6 Issue 8, August 2017

[www.ijsr.net](http://www.ijsr.net)

Licensed Under Creative Commons Attribution CC BY

## 6. Ethical Considerations

The Institutional Ethics Committee of NBMCH approved for our study.

## 7. Acknowledgement

We are grateful and indebted to respected Principal Sir, MSVP Sir, Deputy Superintendent and Assistant Superintendents for being of help whenever needed.

## 8. Source of Funding

We expend from our personal account.

## References

- [1] De Leys R, Vanderborght B, Vanden Haesevelde M, Heyndrickx L, van Geel A, Wauters C, et al. Isolation and partial characterization of an unusual human immunodeficiency retrovirus from two persons of west-central African origin. *J Virol* 1990;64:1207-16.
- [2] Damond F, Descamps D, Farfara I, Telles JN, Puyeo S, Campa P, et al. Quantification of proviral load of human immunodeficiency virus type 2 subtypes A and B using real-time PCR. *J Clin Microbiol*.2001;39:4264–68.
- [3] Peeters M, Toure-Kane C, Nkengasong JN. Genetic diversity of HIV in Africa: Impact on diagnosis, treatment, vaccine development and trials. *AIDS* 2003;17: 2547–60.
- [4] Pieniasek D, Ellenberger D, Janini LM, Ramos AC, Nkengasong J, Sassan-Morokro M, et al. Predominance of human immunodeficiency virus type 2 subtype B in Abidjan, Ivory Coast. *AIDS Res Hum Retroviruses*.1999;15: 603–8.
- [5] Santiago ML, Range F, Keele BF, Li Y, Bailes E, Bibollet-Ruche F, et al. Simian immunodeficiency virus infection in free-ranging sooty mangabeys (*Cercocebus atys atys*) from the Tai Forest, Cote d'Ivoire: Implications for the origin of epidemic human immunodeficiency virus type 2. *J Virol*.2005;79:12515–27.
- [6] Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. *Clin Infect Dis*. 200115;33:865–72.
- [7] Ford N, Calmy A. Improving first-line antiretroviral therapy in resource limited settings. *Current Opin HIV AIDS*.2010;5:38–47.
- [8] Brinkman K. Stavudine in antiretroviral therapy: is this the end? *AIDS*.2009; 23: 1727–29.
- [9] Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, Emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. *N Engl J Med*. 2006;354:251–60.
- [10] Anon. Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Geneva, Switzerland: World Health Organization 2009.
- [11] Beatriz Fernandez-Fernande, Ana Montoya-Ferrer et al. *AIDS Res Treat*. 2011;354908.
- [12] Anti Retroviral Therapy for HIV infected Adults and Adolescents Including Post-exposure Prophylaxis. NACO. Ministry of Health & Family Welfare, Government of India. 2007; A9:37.
- [13] WHO. Anti Retroviral Therapy For HIV infected Adults and Adolescents 2010(revision).
- [14] Srinivas RV, Fridland A. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis (isopropylloxymethylcarbonyl) PMPA against various drug-resistant human immunodeficiency virus strains. *Antimicrob Agents Chemother*. 1998; 42:1484–7.
- [15] Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine(PMPA),Bis(isopropylloxymethylcarbonyl)PMPA. *Antimicrob Agents Chemother*.1998;42:612–7.
- [16] Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. *Clin Pharmacokinet*. 2004;43:595–612.
- [17] Shaw JP, Sueoko CM, Oliyai R, Lee WA, Arimilli MN, Kim CU, et al. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. *Pharm Res*. 1997;14:18249.
- [18] Suo Z, Johnson KA. Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-Phosphonylmethoxypropyl)adenine. *J Biol Chem*. 1998;273:27250–8.
- [19] Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, Cihlar T, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. *Antimicrob Agents Chemother*. 2008;52:3144–60.
- [20] Van Gelder J, Deferme S, Naesens L, De Clercq E, van den Mooter G, Kinget R, et al. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. *Drug Metab Dispos*. 2002;30:924–30.
- [21] Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, Miller M, et al. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus infected adults. *Antimicrob Agents Chemother*. 2001;45:2733–9.
- [22] Hajjar AM, Lewis PF, Endeshaw Y, Ndinya-Achola J, Kreiss JK, Overbaugh J. Efficient isolation of human immunodeficiency virus type1 RNA from cervical swabs. *J Clin Microbiol*. 1998;36:2349–52.
- [23] Cundy KC, Sueoka C, Lynch GR, Griffin L, Lee WA, Shaw JP. Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. *Antimicrob Agents Chemother*. 1998;42:687–90.
- [24] Robbins BL, Greenhaw J, Connelly MC, Fridland A. Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells. *Antimicrob Agents Chemother*. 1995;39:2304–8.
- [25] Robbins BL, Wilcox CK, Fridland A, Rodman JH. Metabolism of tenofovir and didanosine in quiescent or

stimulated human peripheral blood mononuclear cells. *Pharmacotherapy*. 2003;23:695–701.

[26] Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentre F, Taburet AM. Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action. *Clin Pharmacokinet*. 2010;49:17–45.

[27] Kearney B, Flaherty J, Sayre J. A multiple-dose randomized, crossover drug interaction study between tenofovir DF and lamivudine or didanosine. The 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires. 2001 Jul 8–11.

[28] Pruvost A, Negrodo E, Theodoro F, Puig J, Levi M, Ayen R, et al. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. *Antimicrob Agents Chemother*. 2009;53:1937–43.


[29] Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N Engl J Med*. 1998;338:853–60.

[30] Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus zidovudine in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. *N Engl J Med*. 1997;337:725–33.


**Abbreviation**

- HIV- Human Immunodeficiency Virus.
- SIV- Simian Immunodeficiency Virus.
- AIDS- Acquired Immunodeficiency Syndrome.
- AZT –Zidovudine.
- HAART- Highly active antiretroviral therapy.
- NNRTI -Non-nucleoside reverse transcriptase inhibitor.
- TDF-Tenofovir disoproxil fumarate.
- NACO-National Aids control organization.
- ART-Antiretroviral therapy.
- PrEP-Pre-exposure prophylaxis.
- Sd- Standard deviation.
- Hb-Haemoglobin.
- TLC-Total leucocyte count.
- DLC-Differential leucocyte count.

LFT-Liver function test.  
 ALT-Alanine transaminase.  
 NBMC-North Bengal medical college  
 Diagram 1:  
 Distribution of total study population according to age



**Diagram 2:** Distribution of total population according to sex distribution






Figure 1: Change in platelet count (mean  $\pm$  Sd) of total study population observed during the study period.




Figure 2: Change in mean serum creatinine level of total study population observed during the study period.






Figure 3: Change in serum direct bilirubin level (mean  $\pm$  Sd) of total study population observed during the study period.



**Figure 4:** Changes in haemoglobin level (mean+/-Sd) of female population under study observed during study period.



**Figure 5:** Changes in serum alanine aminotranferase

**Table 1:** Tenofovir and renal parameter

Parameter	At initiation	At 1 month	At 3 month	At 6 month
Serum Urea(mean+/-Sd)	21.431+/-5.21	20.784+/-3.14	21.928+/-3.14	22.928+/-3.7
Serum Creatinine(mean+/-Sd)	0.857+/-0.169	0.859+/-0.109	0.883+/-0.1	0.918+/-0.125
Urine for Protein	Trace in 5 pts	Nil	Nil	Nil
Urine for glucose	Present in 1 pts	Nil	Nil	Nil